In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and...

WuXi STA has started up a new parenteral formulation line at its drug product site in Wuxi City, China. The company’s second line for parenteral drug product clinical and...

WuXi STA has opened a sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its campus in Wuxi city, China, in response to rising demand...

WuXi AppTec and its subsidiary Wuxi STA have announced several investments in manufacturing and research in Asia, with the Changzou campus in China’s Jiangsu Province a...

WuXi Advanced Therapies (Wuxi ATU), US-based CDMO offshoot of WuXi AppTec, is joining up with Singapore’s Bioprocessing Technology Institute (BTI) to advance cell and...

China’s WuXi AppTec has acquired British gene therapy CDMO Oxgene, making the Oxford-based company a wholly owned subsidiary of the contract testing, development and...